[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Viome\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":298},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,42,64,97,123,147,172,199,230,259,279],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100590430","human-and-microbial-determinants-of-the-onset-of-ibd-flares-100590430",false,"NCT06967311","Human and Microbial Determinants of the Onset of IBD Flares","Microbial and Human Determinants of the Onset of IBD Flares","Inclusion Criteria:\n\n* Patient at Universidade Federal de Santa Catarina (UFSC) Hospital, under care of Dr. Vivian Menegassi\n\nExclusion Criteria:\n\n* Cancer Diagnosis\u002FTreatment\n* Under 18 years old","ALL","18 Years",{"count":19,"type":20},100,"ESTIMATED","OBSERVATIONAL","This study will collect longitudinal biological samples and survey data to identify the triggers of IBD flares.",[24],"IBD (Inflammatory Bowel Disease)",[26,27,28],"observational","IBD","microbiome","RECRUITING","2025-06-12",{"date":32,"type":33},"2025-06-15","ACTUAL",{"date":35,"type":33},"2025-01-31",{"date":37,"type":20},"2030-02",{"name":39,"class":40},"Viome","INDUSTRY",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":48,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":4},"100593511","systems-biology-of-amyotrophic-lateral-sclerosis-als-100593511","NCT07007390","Systems Biology of Amyotrophic Lateral Sclerosis (ALS)","Inclusion Criteria:\n\n* Patient of Dr. Espíndola at UFSC\n\nExclusion Criteria:\n\n\\-",true,{"count":50,"type":20},20,"The goal of this observational study is to identify molecular features in multiple clinical samples and\u002For the patient environment that are associated with ALS. Participants will collect biological samples and answer questionnaires regarding their health at each appointment with their ALS practitioner.",[53,54],"ALS","ALS (Amyotrophic Lateral Sclerosis)","NOT_YET_RECRUITING","2025-06-02",{"date":58,"type":33},"2025-06-05",{"date":60,"type":20},"2025-06-01",{"date":62,"type":20},"2030-05-01",{"name":39,"class":40},{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":4,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":16,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":4,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":83,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":41},"100554717","viome-precision-nutritional-programs-to-improve-clinical-outcomes-for-mental-health-disorders-100554717","NCT06502717","Viome Precision Nutritional Programs to Improve Clinical Outcomes for Mental Health Disorders","Testing the Efficacy of Viome-designed Condition-based Supplements and Viome Precision Supplements to Improve Clinical Outcomes for Mental Health Conditions","Inclusion Criteria:\n\n* Resident of the United States\n* Females and males ages 25-75 (inclusive)\n* Able to speak and read English\n* No unexplained weight loss, fevers, anemia, or blood in stool\n* Willing and able to follow the trial instructions, as described in the recruitment letter\n* Signed and dated informed consent prior to any trial-specific procedures.\n* PHQ9 score of 5-24 (inclusive)\n\nExclusion Criteria:\n\n* Unwilling to change their current diet\n* Prior use of Viome products or services\n* Antibiotic use in the previous 4 weeks\n* Pregnancy (current or planned in the next 4 months)\n* \\\u003C 90 days postpartum\n* Breast feeding\n* Active infection\n* Unable or unwilling to use Viome's App on an iPhone or Android smartphone\n* Significant diet or lifestyle change in the previous 1 month\n* IBD diagnosis -Major psychiatric\u002FDSM-4 disease diagnosis (e.g. Schizophrenia, Bipolar disorder, Post- traumatic Stress Disorder, Obsessive Compulsive disorder)\n* Use of investigational drugs, products or devices within 1 month prior to and 4 months after the start of the trial\n* Cancer therapy within the previous 1 year\n* Major surgery in the last 6 months or planned in the next 4 months\n* Allergies to any supplement ingredients listed in the screening survey\n* Currently on a specific diet: FODMAP, KETO, PALEO\n* Answered yes to the question, \"In the past few weeks, have you wished you were dead or had thoughts about killing yourself?\"\n* Gastrointestinal disease including:\n\n  * GI surgery except:\n\n    * Appendectomy and benign polypectomy\n* Esophagitis\n* Celiac disease\n* GI malignancy or obstruction\n* Peptic Ulcer Disease\n* Duodenal or gastric ulcer disease","25 Years","75 Years",{"count":74,"type":20},150,"INTERVENTIONAL",[77],"NA","US residents who have mental health issues sign the informed consent form and are screened and enrolled for this study. Participants complete a survey upon enrollment and are randomized into one of two study arms. This study is direct to participant and will NOT utilize clinical sites.",[80,81,82],"Mental Health Issue","Depression","Anxiety",[84,85,86,87,88],"mental health","diet","supplements","vitamins","stress","2025-01-27",{"date":91,"type":33},"2025-01-29",{"date":93,"type":33},"2024-07-08",{"date":95,"type":20},"2025-12",{"name":39,"class":40},{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":106,"conditions":107,"keywords":111,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":117,"startDateStruct":118,"completionDateStruct":119,"leadSponsor":121,"locationsCount":122},"100529488","validity-of-viomes-oralthroat-cancer-test-100529488","NCT06174428","Validity of Viome's Oral\u002Fthroat Cancer Test","Validity of Viome's Oral\u002Fthroat Cancer Test Among Patients with a Suspicion of Cancer","Inclusion Criteria:\n\n* Signed and dated informed consent prior to any study-specific procedures are performed\n* Willing and able to follow the study instructions, as described in the recruitment letter\n* Adults (18 years old or older)\n* Suspicion of OSCC or OPSCC on clinical presentation by a clinician\n\nExclusion Criteria:\n\n* Pregnancy\n* Use of fertility enhancing medications",{"count":105,"type":20},1000,"A total of at least 1,000 participants with suspicion of cancer including at least 107 subjects who will be diagnosed with OSCC or OPSCC will be enrolled from either primary or secondary care centers in the U.S. Clinicians will use Viome collection kits to collect saliva samples from eligible patients.",[108,109,110],"Oral and Throat Cancer","Oropharyngeal Squamous Cell Carcinoma","Oral Squamous Cell Carcinoma",[112,113,114,115,116],"OSCC","OPSCC","Oral Cancer","Throat cancer","Oral and Throat cancer",{"date":91,"type":33},{"date":89,"type":33},{"date":120,"type":20},"2026-12",{"name":39,"class":40},2,{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":129,"targetDuration":4,"studyType":75,"phases":130,"briefSummary":131,"conditions":132,"keywords":134,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":142,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":146,"locationsCount":41},"100530316","efficacy-of-viomes-precision-nutrition-program-towards-reducing-hba1c-100530316","NCT06185192","Efficacy of Viome's Precision Nutrition Program Towards Reducing HbA1c","Inclusion Criteria:\n\n* Signed and dated informed consent form and medical release prior to any trial-specific procedures are performed\n* Females and males aged 18 years or older\n* Able to speak and read English\n* HbA1c between 6.5-8.9% (inclusive), tested within the past 30 days\n* Willing and able to visit a Quest Diagnostic Patient Service Center (PSC)\n* Willing and able to follow the trial instructions and Viome's Precision Nutrition Program\n* Willing and able to use a smartphone and Viome app.\n\nExclusion Criteria:\n\n* Antibiotic use within one month of the GI test\n* Gestation within previous 6 month\n* Current (or previous) use of medications that increase insulin (sulfonylureas, such as glimepiride, glipizide, glyburide, etc.)\n* Current (or previous) use of exogenous insulin (such as Tresiba, Lantus, Toujeo, Levemir, Humalog, Novolog, Apidra, Fiasp, etc.)\n* On a specific diet, such as ketogenic, for the purpose of reducing HbA1c and\u002For weight within the previous month\n* Taking diet pills\n* Allergy to an ingredient in the MH capsule or stick pack\n* Currently on an investigational product\n* Significant surgery or medical procedure planned\n* Diet or lifestyle change during the trial period, besides those appropriate for trial arm Has followed Viome nutritional recommendations (foods and\u002For supplements)",{"count":19,"type":20},[77],"This is a randomized, placebo-controlled trial that will test the efficacy of VPNP in reducing HbA1c. Participant recruitment will occur through direct-to-participant enrollment. No additional clinical sites will be used for recruitment.",[133],"Diabetes",[135,136,137,138,139,140,133,141],"Health","Wellness","Nutrition","Vitamins","Supplements","Blood sugar","Fitness",{"date":91,"type":33},{"date":144,"type":33},"2023-12-13",{"date":120,"type":20},{"name":39,"class":40},{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":16,"minAge":71,"maxAge":72,"enrollmentInfo":154,"targetDuration":4,"studyType":75,"phases":155,"briefSummary":156,"conditions":157,"keywords":159,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":167,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":171,"locationsCount":41},"100482610","viome-nutritional-programs-to-improve-clinical-outcomes-for-metabolic-conditions-100482610","NCT05564273","Viome Nutritional Programs to Improve Clinical Outcomes for Metabolic Conditions","Testing the Efficacy of Viome-designed Condition-based Supplements and Viome Precision Supplements to Improve Clinical Outcomes for Metabolic Conditions","Inclusion Criteria:\n\n* Resident of the United States\n* Females and males ages 25-75 (inclusive)\n* Able to speak and read English\n* No unexplained weight loss, fevers, anemia, or blood in stool\n* Willing and able to follow the trial instructions, as described in the recruitment letter\n* Signed and dated informed consent prior to any trial-specific procedures.\n* Fasting insulin level \\>=15 uIU\u002FmL or fasting glucose \\>= 100 mg\u002FdL within the last 3 months, verified from medical records\n\nExclusion Criteria:\n\n* Unwilling to change current diet\n* Unwilling to go to Quest\n* Prior use of Viome products or services\n* Antibiotic use in the previous 4 weeks\n* Women who are pregnant (current or planned in the next 4 months), or breastfeeding\n* \\\u003C 90 days postpartum\n* Active infection\n* Unable or unwilling to use Viome's App on an iPhone or Android smartphone\n* Significant diet or lifestyle changes in the previous 1 month\n* IBD diagnosis\n* Use of investigational drugs, products or devices within 1 month prior to and 4 months after the start of the trial\n* Cancer therapy within the previous 1 year\n* Major surgery in the last 6 months or planned in the next 4 months\n* Current (or previous) use of medications that increase insulin (sulfonylureas, such as glimepiride, glipizide, glyburide, etc.)\n* Current (or previous) use of exogenous insulin (such as Tresiba, Lantus, Toujeo, Levemir, Humalog, Novolog, Apidra, Fiasp, etc.)\n* Prescribed any drug(s) that may interact with the supplement formulations\n* Have any medical condition or allergy that may interact with, or prevents the healthy consumption of the supplements such as:\n\nPregnancy Breastfeeding Minors GERD Gastric Ulcers Ulcerative Colitis Crohn's Disease Kidney Impairment (kidney cysts, kidney disease) Liver Condition (gallstones, cholecystitis, cirrhosis, hepatitis, hepatitis a, hepatitis b, hepatitis c, NAFLD\u002FNASH, etc) HIV SIBO CuminAllergy GymnemaAllergy BacopaAllergy CitrusAIlergy LamiaceaeAllergy SageAllergy YeastAllergy MulberryAllergy ChicoryAllergy\n\n* Allergies to any study-specific supplement ingredients\n* Currently on a specific diet:\n\nFODMAP KETO PALEO\n\n* Gastrointestinal disease including:\n\n  * GI surgery except:\n\n    * Appendectomy and benign polypectomy\n* Esophagitis\n* Celiac disease\n* GI malignancy or obstruction\n* Peptic Ulcer Disease\n* Duodenal or gastric ulcer disease",{"count":74,"type":20},[77],"US residents who have obesity and sign the informed consent form and are screened and enrolled for this study. Participants who are enrolled complete a survey upon enrollment and are randomized into one of three arms. This study is direct to participant and will not utilize clinical sites.",[158],"Metabolic Health",[160,161,162,163,164,165,166,139,138,85],"BMI","Framingham Risk Score","Insulin","blood glucose","HbA1c","hsCRP","Lipids",{"date":91,"type":33},{"date":169,"type":33},"2023-10-13",{"date":120,"type":20},{"name":39,"class":40},{"id":173,"slug":174,"hasResults":11,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":4,"eligibilityCriteria":178,"healthyVolunteers":48,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":179,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":181,"conditions":182,"keywords":185,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":194,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":198,"locationsCount":41},"100473931","detection-of-oral-and-throat-cancers-using-oralviome-cancer-testing-system-100473931","NCT05451303","Detection of Oral and Throat Cancers Using OralViome Cancer Testing System","Detection of Oral and Throat Cancers Using Saliva Metatranscriptomic Analysis","Inclusion Criteria\n\n* Signed Informed Consent obtained\n* 18 years and older\n* At a high risk of developing oral or throat cancer based on clinician's discretion\n\nExclusion Criteria\n\n* Pregnancy\n* Use of fertility enhancing medications",{"count":180,"type":20},475,"To evaluate the design, safety and efficacy of OralViome Cancer Testing system in the early detection of Oral and Throat Cancers using saliva metatranscriptomic analysis. This study will recruit only at existing clinical sites and will NOT use any additional clinical sites.",[110,183,184],"Oropharynx Squamous Cell Carcinoma","Premalignant Lesion",[39,186,187,112,188,189,190,191,192,193],"oral cancer","detection","OPMD-B","OPMD-PM","OPMD","OPV","Tobacco","HPV",{"date":91,"type":33},{"date":196,"type":33},"2022-05-27",{"date":120,"type":20},{"name":39,"class":40},{"id":200,"slug":201,"hasResults":11,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":4,"eligibilityCriteria":205,"healthyVolunteers":11,"sex":16,"minAge":71,"maxAge":72,"enrollmentInfo":206,"targetDuration":4,"studyType":75,"phases":207,"briefSummary":208,"conditions":209,"keywords":211,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":225,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":229,"locationsCount":41},"100475032","viome-nutritional-programs-to-improve-clinical-outcomes-for-gastrointestinal-conditions-100475032","NCT05465629","Viome Nutritional Programs to Improve Clinical Outcomes for Gastrointestinal Conditions","Testing the Efficacy of Viome-designed Condition-based Supplements and Viome Precision Supplements to Improve Clinical Outcomes for Gastrointestinal Conditions","Inclusion Criteria\n\n* Resident of the United States\n* Females and males ages 25-75 (inclusive)\n* Able to speak and read English\n* No unexplained weight loss, fevers, anemia, or blood in stool\n* Willing and able to follow the trial instructions, as described in the recruitment letter\n* Signed and dated informed consent prior to any trial-specific procedures.\n* Diagnosis of IBS according to ROME IV criteria AND IBS-SSS score of 125-450 (inclusive)\n\nExclusion criteria\n\n* Unwilling to change current diet\n* Prior use of Viome products or services\n* Antibiotic use in the previous 4 weeks\n* Women who are pregnant (current or planned in the next 4 months), or breastfeeding\n* \\\u003C 90 days postpartum\n* Active infection\n* Unable or unwilling to use Viome's App on an iPhone or Android smartphone\n* Significant diet or lifestyle changes in the previous 1 month\n* IBD diagnosis\n* Use of investigational drugs, products or devices within 1 month prior to and 4 months after the start of the trial\n* Cancer therapy within the previous 1 year\n* Major surgery in the last 6 months or planned in the next 4 months\n* Prescribed any drug(s) that may interact with the supplement formulations\n* Have any medical condition or allergy that may interact with, or prevents the healthy consumption of the supplements\n* Allergies to any study-specific supplement ingredients\n* Currently on a specific diet:\n\nFODMAP KETO PALEO\n\n\\- Gastrointestinal disease including: Esophagitis Celiac disease GI malignancy or obstruction Peptic ulcer Duodenal or gastric ulcer disease\n\n* GI surgery except:\n\nAppendectomy and benign polypectomy",{"count":74,"type":20},[77],"US residents who have gastrointestinal issues sign the informed consent form and are screened and enrolled for this study. Participants who are enrolled complete a survey upon enrollment and are randomized into one of three arms. This study is direct to participant and will NOT utilize clinical sites.",[210],"Gastrointestinal Health",[212,213,214,215,216,217,39,137,139,218,219,220,221,222,223,224],"Nausea","Vomiting","Diarrhea","Constipation","Bloating","Gastroesophageal","VPNP","Viome precision nutrition program","Reflux","Diet","Microbiome","Biome","Gastrointestinal",{"date":91,"type":33},{"date":227,"type":33},"2022-11-18",{"date":120,"type":20},{"name":39,"class":40},{"id":231,"slug":232,"hasResults":11,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":4,"eligibilityCriteria":236,"healthyVolunteers":11,"sex":237,"minAge":17,"maxAge":4,"enrollmentInfo":238,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":240,"conditions":241,"keywords":245,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":253,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":41},"100435998","gut-microbiome-and-treatment-for-gynecological-cancer-patients-receiving-immunotherapy-100435998","NCT04957511","Gut Microbiome and Treatment for Gynecological Cancer Patients Receiving Immunotherapy","Pilot Feasibility Study of the Interplay Between the Host Gut Microbiome and Efficacy of Treatment for Advanced or Recurrent Gynecological Cancer Patients Receiving Immunotherapy","Inclusion Criteria:\n\n* Adult females \\> 18 years old\n* Advanced or recurrent gynecological cancer patients from AHMG Advent Health Orlando Gynecologic Oncology Group\n* Patients for whom an immunotherapy regimen has been ordered\n\nExclusion Criteria:\n\n* Patients unable to provide fecal specimens at three time points\n* Patients unable to read or understand informed consent\n* Taking medications that may affect gut microbiome:\n\n  * Proton pump inhibitors (PPIs)\n  * Metformin\n  * Antibiotics\n  * Laxatives\n* Patients who are receiving investigational agent","FEMALE",{"count":239,"type":20},30,"30 participants with advanced or recurrent gynecological cancer from are enrolled for this study. Eligible participants then provide fecal specimen, blood, vaginal swab, oral mucosal swab and receive food dietary recommendation. Additional samples are collected for results analysis.",[242,243,244],"Gynecologic Cancer","Immunotherapy","Gut Microbiome",[223,222,224,246,137,221,39,247,248,249,250,251,252],"Immune check point inhibitors","ICI","ICIs","RNAseq","Anti-tumor immunity","Cancer","Gynecology",{"date":91,"type":33},{"date":255,"type":33},"2021-06-29",{"date":257,"type":20},"2026-06",{"name":39,"class":40},{"id":260,"slug":261,"hasResults":11,"nctId":262,"briefTitle":127,"officialTitle":127,"acronym":4,"eligibilityCriteria":263,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":264,"targetDuration":4,"studyType":75,"phases":265,"briefSummary":131,"conditions":266,"keywords":268,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":41},"100475031","efficacy-of-viomes-precision-nutrition-program-towards-reducing-hba1c-100475031","NCT05465616","Inclusion Criteria:\n\n* Signed and dated informed consent form and medical release prior to any trial-specific procedures are performed\n* Females and males aged 18 years or older\n* Able to speak and read English\n* HbA1c between 5.7-8.9% (inclusive), tested within the past 30 days\n* Willing and able to visit a Quest Diagnostic Patient Service Center (PSC)\n* Willing and able to follow the trial instructions and Viome's Precision Nutrition Program\n* Willing and able to use a smartphone and Viome app.\n\nExclusion Criteria:\n\n* Antibiotic use within one month of the GI test\n* Gestation within previous 6 month\n* Current (or previous) use of medications that increase insulin (sulfonylureas, such as glimepiride, glipizide, glyburide, etc.)\n* Current (or previous) use of exogenous insulin (such as Tresiba, Lantus, Toujeo, Levemir, Humalog, Novolog, Apidra, Fiasp, etc.)\n* On a specific diet, such as ketogenic, for the purpose of reducing HbA1c and\u002For weight within the previous month\n* Taking diet pills\n* Allergy to an ingredient in the MH capsule or stick pack\n* Currently on an investigational product\n* Significant surgery or medical procedure planned\n* Diet or lifestyle change during the trial period, besides those appropriate for trial arm Has followed Viome nutritional recommendations (foods and\u002For supplements)",{"count":74,"type":20},[77],[133,267],"Pre Diabetes",[135,136,137,138,139,269,270,141,140],"Prebiotics","Probiotics","2025-01-21",{"date":273,"type":33},"2025-01-24",{"date":275,"type":33},"2022-08-22",{"date":277,"type":20},"2026-12-13",{"name":39,"class":40},{"id":280,"slug":281,"hasResults":11,"nctId":282,"briefTitle":283,"officialTitle":283,"acronym":4,"eligibilityCriteria":284,"healthyVolunteers":48,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":285,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":287,"conditions":288,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":291,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":297,"locationsCount":41},"100545386","collection-and-analyses-of-physiological-physical-and-molecular-data-from-a-diverse-population-100545386","NCT06381232","Collection and Analyses of Physiological, Physical, and Molecular Data From a Diverse Population","Inclusion Criteria:\n\n* Anyone that resides in the US at the time of enrollment.\n\nExclusion Criteria:\n\n* None",{"count":286,"type":20},20000,"The purpose of the study is to collect and analyze physiological, physical, and molecular data from a diverse population to increase our understanding of how such parameters are associated with health and disease.",[289,136],"General Health","2024-04-18",{"date":292,"type":33},"2024-04-24",{"date":294,"type":33},"2018-07-23",{"date":296,"type":20},"2028-07-23",{"name":39,"class":40},""]